SVC112 / SuviCa - LARVOL DELTA

SVC112: From Hummingbirds to Head and Neck Cancer. (PubMed, Adv Exp Med Biol) - "Bouvardin and SVC112 are found to act on the human ribosome by a previously unknown mechanism. Discovery of bouvardin and development of SVC112 as an oncology agent toward human trials will be discussed in this chapter."

Journal • Review • Head and Neck Cancer • Oncology • Solid Tumor • CHEK1 • TP53

Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers. (PubMed, Sci Rep) - "Apoptosis induction by SVC112 predicts tumor growth control and survival benefit in mouse xenograft models. We suggest a paradigm wherein utility of translation inhibitors is defined by (1) inherent dependence of cancer cells on specific survival factors and (2) post-translational modifications that affect the stability of oncogenic driver proteins."

Journal • Acute Myelogenous Leukemia • Colorectal Cancer • Head and Neck Cancer • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • MYC

Development of a translation elongation inhibitor for the treatment of cancer (AACR 2018) - "In clonogenic assays, physiologically relevant levels of SVC112 robustly synergistically enhance clonogenic death induced by HNC standards of care (e.g. IR and cisplatin). This project has been funded in part with Federal funds from the NCI/NIH, Department of Health and Human Services, under Contract No. HHSN261201300021C"

Acute Myelogenous Leukemia • Head and Neck Cancer

Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma. (PubMed, Cancer Res) - "SVC112 had greater antiproliferative effects on HNSCC cells compared with the FDA-approved translation inhibitor omacetaxine mepesuccinate (HHT). SVC112 increased cell cycle progression delay and slowed DNA repair following radiation, enhancing colony and sphere formation radiation effects. In summary, these data demonstrate that SVC112 suppresses CSC-related proteins, enhances the effects of radiation, and blocks growth of HNSCC PDXs by inhibiting CSCs."

Cancer stem cells • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

BG real room_CancerRes: Phyto-derived SVC112 molecule invades cancer stem cells and threatens the development of head and neck cancer [Google translation] - "Antonio Jimeno...the focus of cancer, said ??????, BG Reality Hall _ It avoids protein closure in a form that its drugs cannot oppose. Once the maintenance is over, it is regulating all cancers. Scientists are distinguishing stem cell-like T cells in tumors. They may be able to distinguish and destroy cancer cells (CSC) as a subgroup of cancer cells. SVC112 is a subgroup of cancer cells."

Media quote

A plant-derived drug attacks cancer stem cells, leaving only healthy cells, according to a study [Google translation] - "'Many other previous works have related the production of transcription factors to the cancer cells that survive, but the inhibitors have simply been very toxic and have many side effects,' explains study co-author Antonio Jimeno, about current drugs....'It is as if the cancer stem cells were in the control tower, directing the growth of the tumor. If it affects enough of these directors, other cancer cells do not know what to do and the growth of cancer slows down or stops,' Jimeno added....Jimeno's team working to understand the basic biology that drives the drug's action, how to best combine it with other treatments such as radiation or immunotherapy, and its potential uses in other types Of cancer."

Media quote

Plant-derived SVC112 hits cancer stem cells, leaves healthy cells alone (Eurekalert) - "'What we saw is that only when you decrease the population of cancer stem cells to under 1 percent of the total makeup of a tumor did the tumor shrink,' Jimeno says. 'It's like cancer stem cells are in the control tower, directing the growth of the tumor. If you impair enough of these directors, other cancer cells don't know what to do and cancer growth slows down or stops.'...'This is the first report of the drug, from the drug's chemical structure, its basic effects on commercial cell lines, to its mechanism of action with patient-derived cell lines and more complex action on CSCs, all the way to animal models from patient samples,' Jimeno says."

Media quote